The goal of this project is to develop an objective, quantitative, and user-friendly digital endpoint to assess nocturnal scratching in children with atopic dermatitis. This endpoint will fulfill a…
Active Definitive Contract Awarded Last action
- Contract number
- 75F40124C00013
- Awardee
-
Emerald Innovations, Inc. UEI MDE4D4W9J7H3
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $1,956,704
Award facts
- Opportunity
-
- FY23 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science Solicitation · FDABAA2300123 · Posted Nov 14, 2022
- Contract value 100% obligated
- $1,956,704.00 Current and potential, with all options
- Completion date 65% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Cambridge, MA 02142, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,956,704 |
About this award
The Food and Drug Administration awarded a $1.956 million definitive contract to Emerald Innovations, Inc. on December 6, 2023, for development of an objective, quantitative, and user-friendly digital endpoint to assess nocturnal scratching in children with atopic dermatitis.
The contract stems from the FDA's Fiscal Year 2023 Broad Agency Announcement for Advanced Research and Development of Regulatory Science, which sought proposals addressing modernization of product development and evaluation for regulatory science. The endpoint will provide a modernized assessment tool for evaluating the efficacy of atopic dermatitis treatments in pediatric and adult populations, addressing an unmet need in clinical evaluation. The contract is firm fixed price with no set-aside and carries a performance period ending May 29, 2028. Work is performed in Cambridge, MA.
Description
The goal of this project is to develop an objective, quantitative, and user-friendly digital endpoint to assess nocturnal scratching in children with atopic dermatitis. This endpoint will fulfill a crucial unmet need by for assessing the efficacy
Quick answers
Who was awarded contract 75F40124C00013?
75F40124C00013 was awarded to Emerald Innovations, Inc. by Food and Drug Administration (Department of Health and Human Services) on December 6, 2023.
How much is contract 75F40124C00013 worth?
The government has obligated $1,956,704 on 75F40124C00013.
Was contract 75F40124C00013 competed?
The extent of competition for 75F40124C00013 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award